CIPROFLOXACIN | N020780 | BAYER HEALTHCARE PHARMACEUTICALS INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
| D. Md. | 2010-02-18 | Terminated 2010-04-20 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition From Angela A Stanton PHD FDA-2014-P-1753 · 7 docket documents Angela A. Stanton, Ph.D. filed this citizen petition on October 27, 2014, requesting that the FDA restrict ciprofloxacin (Cipro), approved under NDAs 19-537, 19-847, 19-857, and 20-780, to life-threatening situations only and limit its availability to emergency rooms, surgical procedures, and intens | Other | 2014-10-29 | Denied | Angela A Stanton PHD |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$1.46
per ml
Lowest NADAC/Unit
$1.25
per ml
Brand NDCs
2
Generic NDCs
0
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 50419077301CIPRO 10% SUSPENSION | $1.46 | ML | Brand | — | 2026-06-17 |
| 50419077701CIPRO 5% SUSPENSION | $1.25 | ML | Brand | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.